Lokon Pharma has announced a collaboration with Affibody to combine oncolytic viruses with Affibody molecules.
“Lokon’s oncolytic adenovirus platform encodes human immunostimulatory genes to induce anti-tumor immunity in cancer patients. We already have one virus in clinical development, LOAd703, and we are expanding our pipeline to meet the demand of different types of malignancies” says Angelica Loskog, the CEO of Lokon Pharma. “Affibody’s proprietary antibody mimetics are small proteins with high affinity to desired targets and well suited to combine with our LOAd platform viruses. We are excited to initiate this new collaboration aiming to develop a novel treatment regime for selected cancer indications.”
A novel treatment regime with adenovirus platforms
“We are enthusiastic about investigating this potential extension of our Affibody technology platform by collaborating with leading researchers in the oncolytic virus field,” says Fredrik Frejd, CSO of Affibody. “The small size of and potential for high affinity makes Affibody molecules highly interesting tools for a novel treatment regime with adenovirus platforms.”
Photo of Angelica Loskog, CEO, Lokon Pharma, and David Bejker, CEO, Affibody